Journal Article

Thrice-Weekly Clarithromycin-Containing Regimen for Treatment of <i>Mycobacterium kansasii</i> Lung Disease: Results of a Preliminary Study

David E. Griffith, Barbara A. Brown-Elliott and Richard J. Wallace

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 37, issue 9, pages 1178-1182
Published in print November 2003 | ISSN: 1058-4838
Published online November 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/378742
Thrice-Weekly Clarithromycin-Containing Regimen for Treatment of Mycobacterium kansasii Lung Disease: Results of a Preliminary Study

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We initiated a prospective trial of an intermittent clarithromycin-containing regimen for the treatment of patients with Mycobacterium kansasii lung disease. Eighteen patients (10 men and 8 women) with M. kansasii lung disease received a regimen consisting of 500–1000 mg of clarithromycin, 25 mg/kg ethambutol, and 600 mg of rifampin 3 times per week. The primary treatment end point was a 12-month period during which sputum cultures were sterile while the patient was receiving therapy. Four male patients were lost to follow-up, but all of the remaining patients successfully completed therapy without significant drug-related adverse events. The mean time (± standard deviation [SD]) to sputum conversion was 1.0 ± 0.9 months, and the mean duration (±SD) of therapy was 13.4 ± 0.9 months. No patient who successfully completed therapy had relapsed after a mean (±SD) of 46 ± 8.0 months. Clarithromycin- and rifampin-containing regimens offer the possibility of effective short-course and intermittent treatment of M. kansasii lung disease.

Journal Article.  3106 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.